Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CVS/Caremark merger

This article was originally published in The Tan Sheet

Executive Summary

Caremark Rx announces Jan. 7 its merger with CVS will "result in new and broader disease management and wellness services delivered through Caremark's and CVS's combined 21,000 pharmacists and nurse practitioners along with Caremark's analytic capabilities and clinical programs." The Nashville, Tenn.-based firm says its pending combination with CVS will "define and lead the next evolution of the pharmaceutical services industry." In response to a lawsuit filed by Express Scripts, CVS says: "This is just another desperate attempt by Express Scripts to derail a merger that not only has the complete support of both the CVS and Caremark boards, but also has received strong support from customers and employees of both companies." Caremark refused a $26.5 bil. offer Express Scripts made in December...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel